Carregant...
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells. Effective treatment of B cell leukemia...
Guardat en:
| Publicat a: | BioDrugs |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544486/ https://ncbi.nlm.nih.gov/pubmed/25859858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0122-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|